Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy

Ziwei Huang1#, Lou Zhong2#, Jianwei Zhu3, Hua Xu1, Wenjing Ma1, Lilei Zhang1, Yuntian Shen1, Betty Yuen-Kwan Law4, Fei Ding1, Xiaosong Gu1, Hualin Sun1

1Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair, Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China; 2Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, China; 3Department of Orthopedics, Affiliated Hospital of Nantong University, Nantong, China; 4State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China

Contributions: (I) Conception and design: H Sun; (II) Administrative support: X Gu, F Ding; (III) Provision of study materials or patients: Z Huang, L Zhong, L Zhang, W Ma, H Xu, J Zhu, Y Shen; (IV) Collection and assembly of data: Z Huang, L Zhong, L Zhang, W Ma, H Xu, J Zhu, BYK Law, Y Shen; (V) Data analysis and interpretation: Z Huang, L Zhong, BYK Law, H Xu, J Zhu, Y Shen, W Ma; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors contributed equally to this work.

Correspondence to: Dr. Hualin Sun. Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Jiangsu Clinical Medicine Center of Tissue Engineering and Nerve Injury Repair, Co-innovation Center of Neuroregeneration, Nantong University, 19 Qixiu Road, Nantong 226001, China. Email: sunhl@ntu.edu.cn.

Background: The molecular mechanisms underlying denervated skeletal muscle atrophy with concomitant muscle mass loss have not been fully elucidated. Therefore, this study aimed to attain a deeper understanding of the molecular mechanisms underlying denervated skeletal muscle atrophy as a critical step to developing targeted therapy and retarding the concomitant loss of skeletal muscle mass.

Methods: We employed microarray analysis to reveal the potential molecular mechanisms underlying denervated skeletal muscle atrophy. We used in vitro and in vivo atrophy models to explore the roles of the interleukin 6 (IL-6), Janus kinase (JAK), and signal transducers and activators of transcription 3 (STAT3) in muscle atrophy.

Results: In this study, microarray analysis of the differentially expressed genes demonstrated that inflammation-related cytokines were markedly triggered and IL-6/JAK/STAT3 signaling pathway was strongly activated during denervated skeletal muscle atrophy. The high level of IL-6 enhanced C2C12 myotube atrophy through the activation of JAK/STAT3, while inhibiting JAK/STAT3 pathway by ruxolitinib (a JAK1/2 inhibitor) or C188-9 (a STAT3 inhibitor) significantly attenuated C2C12 myotube atrophy induced by IL-6. Pharmacological blocking of IL-6 by tocilizumab (antibody against IL-6 receptor) and pharmacological/genetic inhibition of JAK/STAT3 pathway by ruxolitinib/C188-9 (JAK/STAT3 inhibitor) and STAT3 short hairpin RNA (shRNA) lentivirus in tibialis anterior muscles could suppress muscle atrophy and inhibit mitophagy, and was accompanied by the decreased expression of atrophic genes (MuRF1 and MAFbx) and autophagy-related genes (PINK1, BNIP3, Beclin 1, ATG7, and LC3B).

Conclusions: Taken together, the results suggest that IL-6/JAK/STAT3 pathway may be a principal mediator in denervated skeletal muscle atrophy, meaning targeted therapy against IL-6/JAK/STAT3 pathway might have potential as a therapeutic strategy for prevention of skeletal muscle atrophy.

Keywords: Denervation; skeletal muscle atrophy; inflammation; IL-6/JAK/STAT3

doi: 10.21037/atm-20-7269

View this article at: http://dx.doi.org/10.21037/atm-20-7269
Introduction

Skeletal muscle atrophy results from a variety of physiopathological conditions, including aging, immobilization, starvation, denervation, sepsis, diabetes, kidney failure, chronic heart failure, and cachexia (1,2). Peripheral nerve injury is becoming more common, resulting in a high incidence of denervated skeletal muscle atrophy, which lead to reduced quality of life, increased morbidity and mortality. In the last 20 years, new insights have been made into the etiology and therapy of skeletal muscle atrophy, but the treatment options for this disorder are still limited and generally unsatisfactory (3-5). Therefore, a deeper understanding of the molecular mechanisms underlying denervated skeletal muscle atrophy is critically required for developing targeted therapy and retarding the concomitant loss of skeletal muscle mass.

The protein homeostasis in skeletal muscles can be disrupted by increased protein degradation and decreased protein synthesis, leading to skeletal muscle atrophy (6,7). The ubiquitin-proteasome pathway and autophagy-lysosome pathway (mitophagy) are two main pathways involved in protein degradation (8-10). The muscle ring-finger-1 (MuRF-1) and muscle atrophy F-box (MAFbx)/atrogin-1, as two muscle-specific E3 ubiquitin ligases, are increasingly expressed during the skeletal muscle atrophy induced by different stimuli, including dexamethasone, disuse, hindlimb suspension, denervation, and cancer cachexia (4,11-16). Autophagy and mitophagy have been proven to play crucial roles in various types of skeletal muscle atrophy. The levels of Bcl2/adenovirus E1B 19 kDa protein-interacting protein 3, microtubule-associated protein 1 light chain 3 (LC3), p62, and PTEN-induced kinase 1 (PINK1) are elevated during chronic kidney disease-induced skeletal muscle atrophy (17). Mitochondrial dysfunction occurs in several types of skeletal muscle atrophy induced by disuse, aging, diabetes, sepsis, and denervation according to the significantly increased expressions of p62, microtubule-associated protein 1 light chain 3-II (LC3-II), and Beclin 1 (6,18-22). Thus, skeletal muscle atrophy is usually accompanied by the activation of proteolytic pathway, and it is important to know which molecules or events regulate the proteolytic pathways.

As an important pathogenic factor, inflammation contributes to the dysfunction of skeletal muscles (23). Inflammation induces proinflammatory cytokine production, which activates the expression of the proteolytic pathway-related genes during skeletal muscle atrophy (24). A proinflammatory cytokine interleukin-1 beta (IL-1β) increases the expression of atrogenes (atrogin 1 and MuRF1) during skeletal muscle atrophy (7). IL-6, as a pleiotropic cytokine, exerts either pro- or anti-inflammatory effects according to different local immune milieus (25,26). IL-6 is also able to regulate muscle metabolic processes, precipitating muscle hypertrophy or muscle wasting (25). For example, IL-6 levels were found to be elevated during muscle wasting in mice suffering from colon-26 carcinoma (27), while IL-6 inhibition was shown to prevent cancer-induced muscle mass loss (28). It is widely acknowledged that IL-6 binds to ubiquitously expressed type 1 cytokine receptor glycoprotein 130 (GP130) to activate Janus kinases (JAKs), which subsequently activate signal transducers and activators of transcription 3 (STAT3) (27). Moreover, in cultured myotubes and skeletal muscle, chronically elevated IL-6 binding to GP130 can induce increased dynamin-1-like protein (DRP-1) and mitochondrial fission 1 protein (FIS-1) expression, which are key proteins in the process of mitochondrial fission (29). Inflammation-sensitive nuclear factor kappa-B (NF-κB) and STAT3 pathways play an essential role in type 2 diabetes mellitus-induced muscle atrophy (30). Accordingly, IL-6, JAK, and STAT3 are all associated with skeletal muscle atrophy, but the detailed regulation of denervation-induced skeletal muscle atrophy by IL-6/JAK/STAT3 is still unclear.

In this study, we used microarray to show that IL-6/JAK/STAT3, an inflammatory signaling pathway, was strongly activated during denervated skeletal muscle atrophy. The in vitro and in vivo evidence demonstrated that the high expression of IL-6 intensified skeletal muscle atrophy through the activation of JAK/STAT3, while the inhibition of IL-6/JAK/STAT3 pathway attenuated skeletal muscle atrophy through depressing the protein degradation pathway. The results suggest that IL-6/JAK/STAT3 pathway may be an important mediator of denervated skeletal muscle atrophy, and thus anti-inflammation could serve as targeted therapy strategy for skeletal muscle atrophy.

We present the following article in accordance with the ARRIVE reporting checklist (available at http://dx.doi.org/10.21037/atm-20-7269).

Methods

Animals and treatments

All experiments involving animals were performed under
a project license (No. S20200312-003) granted by the ethics board of Nantong University, in compliance with the national guidelines for the care and use of animals. Healthy adult male Institute of Cancer Research (ICR) mice (body weight, ~20 g) and adult male Sprague-Dawley (SD) rats (body weight, ~200 g) were provided by the Experimental Animal Center of Nantong University, Nantong, China. Animals were maintained in 22 °C temperature environment, with a 12-h light-dark cycle and free access to standard rodent chow and water.

To create peripheral nerve injury, the animals were anesthetized with an intraperitoneal injection of mixed narcotics (100 mg/kg ketamine plus 10 mg/kg xylazine), and then the right sciatic nerve was transected to produce a 10-mm long nerve defect. The mice were randomized into groups to receive different treatments for 14 days. The animals were grouped as follows (n=6/group): group Den + Rux, mice administered with vehicle plus ruxolitinib (75 mg/kg/d, a JAK1/2 inhibitor); group Den + C188-9, mice administered with vehicle plus C188-9 (a STAT3 inhibitor, 12.5 mg/kg/d); and group Den, mice administered with vehicle alone. In a separate set of experiments, animals were grouped as follows (n=4/group): group Den + STAT3i, tibialis anterior muscle of mice injected with STAT3 short hairpin RNA (shRNA) lentivirus; and group Den, tibialis anterior muscle of mice injected with viral vectors. A control (Ctrl) group consisting of the mice that were subjected to sham operation before treatment with viral vectors for 14 days was also included.

After different treatments, all mice were killed by cervical decapitation, and the tibialis anterior muscle was harvested to be rapidly frozen in liquid nitrogen and stored at –80 °C for subsequent experiments.

Local infusion

An osmotic pump was implanted for delivering recombinant murine IL-6 (rIL-6) to maintain the sustained high level of IL-6 in animal skeletal muscles as described in a previous publication (31). In brief, we subcutaneously implanted (s.c.) osmotic minipumps (Alzet Model 2002; Alza Corp., Mountain View, CA, USA) in normal mice in order to infuse rIL-6 (Beyotime, Nantong, China) to their tibialis anterior muscle through a catheter (i.d. 0.006 in, Alza) at a flow rate of 4.5 pg/h for each muscle. For catheter implantation, the incisions were made in the skin overlying the tibialis anterior muscle, and on the back, and following this, two further small cuts were made into the fascia of the muscle; a catheter was then tunneled under the fascia and secured. The proximal end of the catheter was mated with the pump, which was placed under the skin via the back incision, and then both incisions were closed. The mice infused with vehicle (saline) plus tocilizumab (TCZ, an anti-IL-6 receptor antibody, 5 mg/kg), constituted the Den + TCZ group. The vehicle (saline)-infused mice served as the control (n=6/group). After 14 days, the mouse tibialis anterior muscle was harvested under anesthesia, weighed, snap-frozen in liquid nitrogen, and stored at –80 °C.

Microarray analysis and ingenuity pathway analysis (IPA)

For microarray analysis, SD rats were randomly divided into 11 experimental groups and 1 control group (n=3). The origin and management of animals were the same as those in a previously described study (2). For the experimental groups, the sciatic nerve of rats was transected to leave a 10-mm long defect, and the rats were then euthanized under anesthesia at 0.25, 0.5, 3, 6, 12, 24 h, and at 3, 7, 14, 21, 28 d post-surgery. For control group, the rats were subjected to sham surgery and then sacrificed in the same way. Following rat sacrifice, the tibialis anterior muscle of rats was rapidly dissected and homogenized to extract RNA using a RNasey Mini Kit (Qiagen, Valencia, CA, USA) according to the kit guidelines. For microarray analysis of RNA samples, standard protocols were followed (2). After total RNA was transcribed into complement RNA (cRNA), the cRNA labeled with Cy3 was assembled into the Agilent SurePrint G3 Rat GE 8×60 k microarray (Agilent, Santa Clara, CA, USA). The GeneSpring software (version 13.1) was used for normalization and transformation of raw data. The messenger RNA (mRNA) expression in the experimental groups (corresponding to different time points post-surgery) was compared to that in the control group (0 h post-surgery). The differentially expressed genes were considered to be those having an mRNA expression with a fold difference of >2 and a P value of <0.05. The differentially expressed inflammation-related genes were subjected to gene interaction analysis using IPA software (Ingenuity, Redwood, CA, USA).

Cell culture and treatments

To induce the differentiation of C2C12 myoblast cells into myotubes, the cells were cultured in the presence of 2%
horse serum [American Type Culture Collection (ATCC), Manassas, VA, USA] for 7 days with a medium change completed every 2 days (6). Then, the resulting C2C12 myotubes were treated for 12 h in the presence or absence of IL-6, or treated for 12 h with IL-6 plus JAK1/2 inhibitor, or with IL-6 plus STAT3 inhibitor, before morphometric examination and biochemical assessments.

**Quantitative real-time polymerase chain reaction (qRT-PCR)**

A RNeasy kit (Qiagen, Valencia, CA, USA) was used to extract total RNA from rat tibialis anterior muscles. The cDNA was synthesized and qRT-PCR was conducted using iTaq Fast SYBR Green Supermix (BioRad, Hercules, CA, USA) as per the manufacturer’s instructions under the following conditions: 42 °C for 20 min, 40 cycles at 95 °C for 5 min, 94 °C for 20 s, 72 °C for 42 s (4). The expression level was calculated using the 2\(^{-\Delta\Delta Ct}\) method as previously reported (32). The primers used were the following: rat IL-6R (NM_017020) 5’-GGCAACCTTATGCTCAT-3’, 5’-CTGTCTGCTCCAGCCTTGA-3’; rat JAK2 (NM_031514) 5’-GAGCTACTGAAACCAACGG-3’, 5’-TGAAAGAGGGAGAGTTAGGA-3’; rat STAT3 (NM_012747) 5’-GTCTGAATTAGGGCAGTGAG-3’, 5’-CAGGGAAAGGAGAAGACATGA-3’; rat ACTB (NM_031144.2) 5’-CCACCATGTACCCAGGCATT-3’, 5’-CGGACTCATCTCGACTTGC-3’.

**Western blot analysis**

Western blot analysis was performed to determine the protein expression as previously described (33). The total proteins were extracted with radioimmunoprecipitation assay (RIPA) lysis buffer containing protease and phosphatase inhibitor cocktail (Beyotime), and quantified using BCA Kit (Beyotime), followed by separation on SDS-PAGE and transferring to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA), which were then reacted with different primary antibodies at 4 °C overnight. The primary antibodies included mouse anti-myosine heavy chain (MHC) antibody (R&D Systems, Minneapolis, MN, USA), rabbit anti-MuRF1, rabbit anti-MAFbx (Fbx32), rabbit anti-LC3B, rabbit anti-PINK1, rabbit anti-BNIP3, rabbit anti-ATG7, rabbit anti-Beclin 1, rabbit anti-beta tubulin (Abcam, Cambridge, UK), mouse anti-pJak1 (Tyr705), and rabbit anti-Stat3 (Cell Signaling Technology, Danvers, MA, USA). Then, the membranes were incubated with horse radish peroxidase (HRP)-conjugated secondary immunoglobulin G (IgG) antibodies for 2 h. The target proteins were detected using enhanced chemiluminescence (Thermo Fisher Scientific, USA), and the band intensity was quantified and normalized against loading control.

**Determination of muscle fiber cross-sectional area (CSA)**

The muscle fiber CSA was measured using laminin staining as previously described (4,6). Briefly, all mouse tibialis anterior muscles were fixed, flash-frozen, and cryosectioned into 10-μm thick sections. The middle third of each muscle was sliced. The sections were incubated in the presence of anti-laminin antibody (Abcam) at 4 °C for 12 h, and then incubated with fluorescent secondary antibody (Alexa Fluor, Invitrogen, USA) at room temperature for 1 h. Five slices were selected from each muscle sample. The slides were observed and imaged under fluorescence microscopy (ZEISS, Oberkochen, Germany) and the CSA was determined using ImageJ software [National Institutes of Health (NIH), Bethesda, MD, USA] through blinded analysis of five randomly captured images under each detection condition.

**Enzyme-linked immunosorbent assay (ELISA)**

ELISA was conducted for measuring the IL-6 content as previously described (4). In brief, ELISA plates (Beyotime) were incubated in 100 μL lysates of the mouse tibialis anterior muscles or in 100 μL serum at 37 °C for 2 h. The
plates were then washed and incubated in the presence of biotinylated polyclonal anti-IL-6 antibody at 37 °C for 1 h. The plates were further washed and incubated in the presence of HRP-conjugated streptavidin at 37 °C in dark for 20 min. Finally, the absorbance was read at 450 nm using a spectrophotometer, and the enzyme activity was calculated to determine the IL-6 content.

**Transmission electron microscopy (TEM) analysis**

TEM was used to observe the mitochondrial changes in muscle samples as previously described (19). The samples were fixed with a solution of 3% glutaraldehyde in phosphate-buffered saline (PBS). Following orientation and reduction to an optimal size of 1–2 mm³, samples were post-fixed in 1% osmium tetroxide (OsO₄) in cacodylate buffer, dehydrated in graded ethanol, and embedded in ARALDITE® (Huntsman Corp., TX, USA). The sections were stained with uranyl acetate and lead citrate, and visualized under TEM (Hitachi, Tokyo, Japan).

**Statistical analysis**

The data are expressed as means ± SD and were analyzed by one-way ANOVA plus Tukey’s post hoc pairwise comparisons through GraphPad Prism software (version 8.0.1, San Diego, CA, USA). A P value <0.05 was considered as statistically significant.

**Results**

**Activation of IL-6/JAK/STAT3 signaling pathway in denervated skeletal muscle atrophy**

Inflammation is known to be related to skeletal muscle atrophy in critically ill patients (7,23,35). Our previous report has also indicated that inflammation plays a role in skeletal muscle atrophy induced by denervation (2). In this study, the heatmap from microarray data showed a differential expression profile of inflammation-related genes in denervated rat tibialis anterior muscles. The expression of inflammation-related genes can be divided into two main patterns. One pattern was featured by time-dependently increased expression of genes, including JAK2, JAK3, STAT3, NF-κB2, and IL17RA, especially at 24 h post denervation. Another pattern displayed an opposite trend, specifically, a time-dependent decrease in the expression of the CAV1, CaSR, ALOX15, and MAPKPK genes, especially at 24 h post denervation (Figure 1A). These data suggested that inflammation was markedly induced. To further analyze the interaction between these inflammation-related genes, IPA revealed that IL-6R, JAK2, and STAT3 were all activated and there was a connection between them (Figure 1B). The mRNA levels of IL-6R, JAK2, or STAT3 during denervation-induced muscle atrophy were also determined by qRT-PCR, and the results were consistent with microarray data (Figure 1C,D,E), which provided further evidence for IL-6/JAK/STAT3 signaling pathway being activated during denervation-induced muscle atrophy.

As a well-known inflammatory signaling pathway, IL-6/JAK/STAT3 exerts a crucial function during cachexia-induced skeletal muscle atrophy (27). To determine the activation of this signaling pathway during denervated skeletal muscle atrophy, we determined the IL-6 content in serum or tibialis anterior muscles of mice through ELISA, and found that the IL-6 content was time-dependently increased at different times after denervation (Figure 2A). We further determined the expression of phosphorylated JAK1/2 (pJAK1/2) and pSTAT3 through western blot analysis, and found that the expression of pJAK1/2 and pSTAT3 was time-dependently increased in mouse tibialis anterior muscles after denervation (Figure 2B,C,D). Taken together, these results suggested that IL-6/JAK/STAT3 signaling pathway might be substantively activated during denervation-induced muscle atrophy.

**Importance of IL-6 in denervated skeletal muscle atrophy**

To explore the role of IL-6 in denervated skeletal muscle atrophy, osmotic pumps were implanted in normal mice to deliver rIL-6, thus maintaining high levels of IL-6 in tibialis anterior muscles. This method does not significantly increase the level of circulating IL-6. We noted that delivering rIL-6 into mice tibialis anterior muscle led to tibialis anterior muscle atrophy, as evidenced by the smaller muscle wet weight and the smaller mean CSA of the tibialis anterior muscles in mice administered with rIL-6 compared with those in mice administered with vehicle (saline) (Figure 3A,B,C,D). These data suggested that the impact of IL-6 on skeletal muscles was similar to that of denervation on skeletal muscles. Meanwhile, the IL-6 content was high in the denervated tibialis anterior muscles and in the rIL-6-treated tibialis anterior muscles (Figure 3E). To determine whether IL-6 blocking could alleviate denervation-induced...
skeletal muscle atrophy, we noted that tocilizumab, an anti-IL-6 receptor antibody, could reduce the tibialis anterior muscle atrophy induced by denervation (Figure 3A,B,C,D), indicating the critical importance of IL-6 in denervation-induced skeletal muscle atrophy.

Interestingly, the expression of pJAK1/2 or pSTAT3...
Figure 2 IL-6/JAK/STAT3 signaling pathway is markedly activated during denervation-induced muscle atrophy. (A) The content of inflammatory cytokines IL-6 in serum (left) or tibialis anterior muscles (right) of mice after denervation was determined by ELISA. (B) Representative western blot images of pJAK1/2, pSTAT3, and STAT3 in mouse tibialis anterior muscles at 1, 3, 7, 14, and 28 d after denervation. (C,D) Quantification of pJAK1/2 and pSTAT3 from western blot in mouse tibialis anterior muscles after denervation (n=3). *, P<0.05; **, P<0.01; and ***, P<0.001 vs. Ctrl (0 h post-surgery).

in denervated and rIL-6-administered tibialis anterior muscles was significantly increased compared to that in vehicle (saline)-administrated tibialis anterior muscles. The expression of the ubiquitin proteasome system (MAFbx and MuRF1) and autophagy lysosomal system (PINK1, BNIP3) also displayed a similar change (Figure 3F–G). Inversely, the MHC expression in denervated and rIL-6-administered tibialis anterior muscles was decreased compared to that in vehicle (saline)-administered tibialis anterior muscles. Importantly, all of the above expression changes could be reversed by application of tocilizumab in denervated tibialis anterior muscles (Figure 3F,G). These observations suggested that IL-6 was important in denervated skeletal muscle atrophy and critical for the activation/phosphorylation of JAK/STAT3.

Effects of JAK/STAT3 inhibition on IL-6 induced C2C12 myotube atrophy

In determining the in vitro effects of JAK/STAT3 inhibition
Figure 3 IL-6 is critical for denervation-induced skeletal muscle atrophy. Mice were (s.c.) implanted with Alzet osmotic minipumps for delivering vehicle (saline) plus recombinant murine IL-6 (rIL-6 group), vehicle (saline) plus 5 mg/kg (i.p.) tocilizumab, an anti-IL-6 receptor antibody (Den + TCZ group), or vehicle (saline) alone (Den group) for 14 days. After sham operation, mice were administered with vehicle (saline; Ctrl group) for 14 days. Then, the tibialis anterior muscles were harvested to undergo laminin staining analysis. (A) Representative images of laminin-stained tibialis anterior muscle cross-sections in each group. Green indicates laminin staining. Scale bar: 50 μm. (B) The ratio of tibialis anterior muscles wet weight in each group. (C) The mass of tibialis anterior muscles in each group. (D) The cross-sectional area (CSA) in TA fibers in each group. (E) The content of inflammatory cytokine IL-6 in tibialis anterior muscles was determined by ELISA. (F) Representative western blot image of pJAK1/2, pSTAT3, LC3B, BNIP3, PINK1, MHC, MuRF1, and MAFbx in tibialis anterior muscles. (G) Quantification of pJAK1/2, pSTAT3, LC3B, BNIP3, PINK1, MHC, MuRF1, and MAFbx from western blot in tibialis anterior muscles. *, P<0.05; **, P<0.01; and ***, P<0.001 vs. Ctrl. #, P<0.05; ##, P<0.01; and ###, P<0.001 vs. Den + TCZ.

on IL-6 induced skeletal muscle atrophy, we observed that exposure of C2C12 myotubes to rIL-6 (100 ng/mL) for 24 h could elicit a significant decrease in the diameter of C2C12 myotubes compared to exposure to vehicle (saline) alone for 24 h (Figure 4A). The wasting of C2C12 myotubes elicited by rIL-6 was accompanied by the increased expression of...
Figure 4 JAK/STAT3 inhibition blocks IL-6-induced C2C12 myotube atrophy. C2C12 myotubes were treated with 100 ng/mL rIL-6 (rIL-6 group), rIL-6 plus 400 nM ruxolitinib (rIL-6 + Rux group), rIL-6 plus 10 μM C188-9 (rIL-6 + C188-9 group), or with vehicle (DMSO) (Ctrl group). (A) Representative images of MHC-stained C2C12 myotubes and the histogram showing the diameters of C2C12 myotubes. Green indicates MHC staining. Scale bar: 20 μm. ***, P<0.001; and ****, P<0.0001 vs. Ctrl. #, P<0.05 vs. rIL-6. (B) Representative western blot images and the relative expression of pJAK1/2, pSTAT3, MHC, MuRF1, and MAFbx in C2C12 myotubes. *, P<0.05; **, P<0.01; ***, P<0.001; and ****, P<0.0001 vs. Ctrl. #, P<0.05; and ###, P<0.001 vs. rIL-6 + Rux. (C) Representative western blot images and the quantification of pJAK1/2, pSTAT3, MHC, MuRF1, and MAFbx from western blot in C2C12 myotubes. *, P<0.05; **, P<0.01; and ***, P<0.001 vs. Ctrl. *#, P<0.05 vs. rIL-6 + C188-9.
pJAK1/2, pSTAT3, MAFbx, MuRF1, and the decreased expression of MHC (Figure 4B,C). When C2C12 myotubes were treated with 400 nM ruxolitinib (a JAK1/2 inhibitor) or 10 μM C188-9 (a STAT3 inhibitor) in the presence of 100 ng/mL rIL-6 for 24 h, the signaling of JAK/STAT3 was blocked, the expression of MAFbx and MuRF1 decreased, the expression of MHC increased, and the atrophy of C2C12 myotubes was inhibited (Figure 4A,B,C). These results suggested that pharmacological depression of JAK/STAT3 could block IL-6-induced C2C12 myotube atrophy in vitro.

**Effects of JAK/STAT3 inhibition on denervated skeletal muscle atrophy**

We also examined the effects of JAK/STAT3 inhibition on denervated skeletal muscle atrophy in vivo. In the mice with sciatic nerve injury, the ratio of wet weight and CSA of denervated tibialis anterior muscles were significantly decreased compared to those of control tibialis anterior muscles from sham operation mice. After administration with ruxolitinib or C188-9 for 14 days, results showed that JAK/STAT3 inhibition treatment significantly reversed the above-mentioned decrease in mice with sciatic nerve injury when compared to the control group (Figure 5A); meanwhile, JAK/STAT3 inhibition with Rux and C188-9 did not significantly change the mass of the contralateral muscles. Concomitantly, the expression of MAFbx and MuRF1 was inhibited while MHC content was elevated in denervated tibialis anterior muscles in the JAK/STAT3 inhibition treatment group compared to that in the control group. Moreover, ruxolitinib and C188-9 dramatically inhibited JAK/STAT3 signaling, as shown by the decreased expression of pJAK1/2 or pSTAT3 in denervated muscles (Figure 5B,C). In addition to using STAT3 inhibitors, STAT3 shRNA lentivirus (STAT3i) were used to knockdown STAT3 in denervated muscles. Similar to STAT3 inhibitors, STAT3i could also significantly improve the decrease of the wet weight and CSA of the denervated muscles, decrease the expression of pSTAT3, MAFbx, and MuRF1, and increase the content of MHC in muscles after denervation (Figure 6A,B,C), which suggested that STAT3 activation was necessary for denervated skeletal muscle atrophy in vivo. These data demonstrated that JAK/STAT3 inhibition could alleviate denervated skeletal muscle atrophy in vivo.

**Effects of STAT3 knockdown on mitophagy in denervated skeletal muscles**

Mitophagy is associated with the degree of muscle atrophy (36,37). In exploring the effects of STAT3 knockdown on mitophagy in denervated skeletal muscle atrophy, we noted that autophages and autophagic vesicles could be easily observed in denervated muscles under TEM (Figure 7A). Meanwhile, the expression of the mitophagy markers, including BNIP3, PINK1, LC3B, Beclin 1, and ATG7, were increased in denervated muscles (Figure 7B). On the other hand, STAT3 knockdown significantly inhibited mitophagy, as indicated by the decrease in the number of autophages and autophagic vesicles, and the significantly reduced expression of PINK1, BNIP3, LC3B, ATG7, and Beclin 1 (Figure 7A,B). These results suggested that STAT3 knockdown could block mitophagy in denervated skeletal muscles.

**Discussion**

Dysregulation in the muscle microenvironment is liable to induce skeletal muscle atrophy (4,38), and inflammation, as an important factor in changing the muscle microenvironment (39), should thus also play a critical role in skeletal muscle atrophy (24). An abundance of research has attested to the associations of skeletal muscle atrophy with inflammation. For instance, IL-1β was found to increase atrogene expression to induce skeletal muscle atrophy in sepsis (7), an elevated level of tumor necrosis factor alpha (TNF-α) was demonstrated to inhibit the regenerative potential of satellite cells in dystrophic muscle by silencing Notch 1 (25), and the IL-6/JAK/STAT3 pathway has been shown to be aberrantly hyperactivated in many types of cancer (40,41), leading to skeletal muscle atrophy in cancer cachexia (27,28). Madaro et al. found that IL-6 was significantly induced in fibro-adipogenic progenitors of muscles after denervation and figured prominently in muscle atrophy (42).

Despite the above findings, whether or not the inflammatory IL-6/JAK/STAT3 pathway is markedly activated in denervated skeletal muscle atrophy has not been thoroughly examined. Our previous study indicated the inflammatory response to be widely activated in tibialis anterior muscles of rats undergoing sciatic nerve transaction (2). This finding is consistent with the previously reported results regarding the involvement of
Figure 5 JAK/ STAT3 inhibition alleviates denervation-induced muscle atrophy. After denervation, mice were administrated with 75 mg/kg/d ruxolitinib (Den + Rux group), 12.5 mg/kg/d C188-9 (Den + C188-9 group), or with vehicle (DMSO + saline; Den group) for 14 days. After sham operation, mice were administered with vehicle (DMSO + saline; Ctrl group) for 14 days. Then, the TA muscles were harvested to undergo laminin staining analysis. (A) Representative images of laminin-stained TA muscles cross-sections in each group, the histogram showing the ratio of TA muscles wet weight, and the mass and CSA of TA muscles in each group. Green indicates laminin staining. Scale bar: 50 μm. **, P<0.01; ***, P<0.001; and ****, P<0.0001 vs. Ctrl. #, P<0.05; and ###, P<0.001 vs. Den. (B) Representative western blots of pJAK1/2, pSTAT3, MHC, MuRF1, and MAFbx in TA muscles in each group. (C) Representative western blot images and the quantification of pJAK1/2, pSTAT3, MHC, MuRF1, and MAFbx from western blot in each group. *, P<0.05; and ***, P<0.001 vs. Ctrl. #, P<0.05 vs. Den + C188-9.
inflammation in sepsis or cancer-induced skeletal muscle atrophy (7,23,35). In this study, we attempted to further analyze the distinct expression profiles of inflammation-related genes during denervated muscle atrophy. The expression profiles could be divided into two main patterns: a primarily time-dependent increase of expression for...
proinflammatory factors, and a primarily time-dependent decrease of expression for anti-inflammatory factors. These two opposing trends suggested that inflammation was linked to denervated skeletal muscle atrophy. IPA of these differentially expressed genes indicated that IL-6R, JAK2, and STAT3 might be activated and interconnected. It is known that the binding of IL-6 to its receptor, IL-6R, can activate three signaling pathways: SHP2/PI3K/AKT2, SHP2/MEK/ERK, and JAK/STAT3 (43-45). The microarray data in this study showed that IL-6R, JAK2, and STAT3 were all upregulated during denervated skeletal muscle atrophy, prompting speculation that the binding of IL-6 to IL-6R could activate JAK/STAT3 signaling pathway to act on denervation-induced skeletal muscle atrophy. We found that the expression of pJAK1/2, pSTAT3, and particularly IL-6 was increased in denervated muscles, implying that IL-6/JAK/STAT3 signaling pathway was significantly activated during denervation-induced muscle

**Figure 7** STAT3 knockdown inhibits mitophagy during denervation-induced muscle atrophy. After denervation, the TA muscles were injected with LV-shSTAT3-RNAi (Den + STAT3i group) or viral vectors (Den group) for 14 days. After sham operation, the TA muscles were administered with viral vectors (Ctrl group) for 14 days. (A) Representative TEM images of TA muscles in each group. The black arrow indicates normal mitochondria between muscle fibers. The white arrow indicates an autophagosome or an autophagic vesicle. The histograms showing the number of vacuoles per 100 mitochondria in TA muscles from each group. Bar: 2 μm for upper and 1 μm for lower. (B) Representative western blot images and the quantification of BNIP3, PINK1, LC3B, Beclin 1, and ATG7 from western blot in TA muscles from each group. *, P<0.05; **, P<0.01; ***, P<0.001; and ****, P<0.0001 vs. Ctrl. #, P<0.05; ##, P<0.01; and ###, P<0.001 vs. Den + STAT3i.
atrophy. This finding is consistent with other studies (27,28,46,47). For instance IL-6 was demonstrated to induce cachexia, resulting in muscle wasting, while IL-6 inhibition could retard cachexia-induced skeletal muscle wasting (28). Another study showed that STAT3 was a primary mediator of skeletal muscle wasting in cancer cachexia, while STAT3 inhibition retarded cancer-induced skeletal muscle wasting (27,48).

We found that IL-6 administration led to skeletal muscle atrophy, indicating that the influence of IL-6 on skeletal muscles was similar to the that of denervation on skeletal muscles. In contrast, inhibition of IL-6 signaling prevented denervation-induced muscle atrophy, suggesting that IL-6 was both sufficient and necessary for denervated skeletal muscle atrophy. The impact of IL-6 on denervated muscle atrophy was consistent with the impact of IL-6 on cachexia as described previously (28). Evidence from clinical trials, however, indicated that inhibition of IL-6 signaling could not completely retard cancer-induced skeletal muscle atrophy, which might be due to the many other factors involved in cancer-induced skeletal muscle atrophy (49).

In this study, we showed that pJAK1/2 and pSTAT3 had a higher expression in the denervated and IL-6 injected skeletal muscles. Similar to pJAK1/2 and pSTAT3, the ubiquitin proteasome system and autophagy lysosomal system were also found to exhibit significantly elevated expression. Moreover, the expression changes of all these cytokines were reversed by IL-6 signaling blocking in denervated skeletal muscles, which provided further evidence that IL-6 may be critical to JAK/STAT3 activation.

IL-6 activates JAKs, which subsequently activate STAT3 to promote the transcription of several genes in cancer cachexia (27,40). In this study, the in vitro and in vivo experiments investigated the role of the JAK downstream of IL-6 in denervated skeletal muscle atrophy. The elevated expression of pJAK1/2 and pSTAT3 was observed in IL-6-induced C2C12 myotube atrophy, while ruxolitinib inhibition of JAK1/2 prevented the activation of JAK/STAT3, thus alleviating myotube atrophy. JAK1/2 inhibition could block IL-6-induced myotube atrophy in vitro. Similarly, JAK1/2 inhibition could alleviate denervation-induced skeletal muscle atrophy. These findings are consistent with previous findings in which JAK inhibition prevented STAT3 phosphorylation during controlled mechanical ventilation, thus alleviating diaphragm atrophy and blunting the activation of proteolytic pathways (50).

JAK/STAT pathway triggers muscle protein loss in cancer cachexia (51), while STAT3 accelerates the activation of the ubiquitin proteasome system and contributes to skeletal muscle atrophy in type 2 diabetes mellitus (30). Moreover, STAT3 can impair the protein synthesis in skeletal muscles of mice suffering from chronic kidney disease or cancer cachexia, while STAT3 inhibition can attenuate chronic kidney disease–induced skeletal muscle atrophy (30,52). Here, we found that STAT3 blocking significantly decreased the expression of pSTAT3 and markedly alleviated C2C12 myotube atrophy, but had no effects on JAK activation. A similar result was also observed in an in vivo model, whose creation was prompted by the discovery that blocking STAT3 relieved denervation-induced skeletal muscle atrophy, and was accompanied by the deactivation of STAT3, the decreased expression of MAFbx and MuRF1, and the increased expression of MHC. These results are also in line with those of another previous study which reported that blocking STAT3 could suppress the expression of caspase-3, MAFbx, and myostatin, thus alleviating skeletal muscle wasting in cancer cachexia (51).

Inhibition of STAT3 signaling has been known to decrease TNF-α-induced autophagy (53). Similarly, this study showed that STAT3 knockdown significantly inhibited mitophagy after denervation, indicating that the activation of STAT3 was necessary for denervation-induced skeletal muscle atrophy; conversely, the local inhibition of STAT3 in skeletal muscles could reduce mitophagy in denervated skeletal muscles.

To summarize, this study revealed a previously unappreciated involvement of the IL-6/JAK/STAT3 signaling pathway in denervated skeletal muscle atrophy. Inflammatory cytokine IL-6 was triggered in denervated skeletal muscles, leading to the activation of JAK and the ensuing activation of STAT3. Phosphorylation of STAT3 resulted in nuclear localization and atrogene expression (Figure 8). The inhibition of IL-6 through tocilizumab (an anti-IL-6 receptor antibody), inhibition of JAK through ruxolitinib (a JAK1/2 inhibitor), or inhibition of STAT3 through C188-9 (a STAT3 inhibitor) or STAT3 shRNA lentivirus, could alleviate skeletal muscle atrophy through suppression of proteolysis. Our findings support IL-6/JAK/STAT3 as a potential therapeutic target for skeletal muscle atrophy.
Figure 8 A schematic diagram illustrating the proposed mechanism by which peripheral nerve injury induces skeletal muscle atrophy. Denervation-induced skeletal muscle atrophy is associated with the activated inflammatory signaling pathway, IL-6/JAK/STAT3. The inhibition of IL-6 through tocilizumab (an anti-IL-6 receptor antibody), inhibition of JAK through ruxolitinib (a JAK1/2 inhibitor), or inhibition of STAT3 through C188-9 (a STAT3 inhibitor) alleviated denervation-induced skeletal muscle atrophy by reducing proteolysis.

Acknowledgments

We thank Professor Jie Liu for his help in revising the manuscript.

Funding: This work was supported by the National Natural Science Foundation of China (No. 82072160, 81871554, 81671230, and 81901933), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the Major Natural Science Research Projects in Universities of Jiangsu Province (No. 20KJA310012), and the Natural Science Foundation of Jiangsu Province (No. BK20201209).

Footnote

Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at http://dx.doi.org/10.21037/atm-20-7269

Data Sharing Statement: Available at http://dx.doi.org/10.21037/atm-20-7269

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-7269). The authors have no conflicts
of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Experiments were performed under a project license (No. S20200312-003) granted by the ethics board of Nantong University, in compliance with the national guidelines for the care and use of animals.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**


(English Language Editor: J. Gray)